Founders Capital Management (Connecticut)’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.74M Sell
22,823
-70
-0.3% -$15.1K 0.86% 24
2026
Q1
$4.98M Hold
22,893
0.82% 27
2025
Q4
$5.23M Buy
22,893
+32
+0.1% +$7.29K 0.78% 26
2025
Q3
$5.29M Sell
22,861
-69
-0.3% -$14.1K 0.83% 25
2025
Q2
$4.26M Hold
22,930
0.72% 26
2025
Q1
$4.8M Sell
22,930
-87
-0.4% -$16.9K 0.88% 26
2024
Q4
$4.09M Sell
23,017
-377
-2% -$69.3K 0.72% 26
2024
Q3
$4.62M Sell
23,394
-332
-1% -$62K 0.8% 28
2024
Q2
$4.07M Hold
23,726
0.73% 27
2024
Q1
$4.32M Buy
23,726
+800
+3% +$138K 0.8% 27
2023
Q4
$3.55M Hold
22,926
0.73% 28
2023
Q3
$3.42M Buy
22,926
+70
+0.3% +$10.3K 0.78% 28
2023
Q2
$3.08M Hold
22,856
0.69% 31
2023
Q1
$3.64M Hold
22,856
0.91% 25
2022
Q4
$3.69M Hold
22,856
0.99% 25
2022
Q3
$3.07M Hold
22,856
0.86% 26
2022
Q2
$3.5M Hold
22,856
0.9% 24
2022
Q1
$3.71M Hold
22,856
0.8% 27
2021
Q4
$3.1M Sell
22,856
-260
-1% -$30.7K 0.67% 31
2021
Q3
$2.49M Buy
23,116
+415
+2% +$47.4K 0.63% 31
2021
Q2
$2.56M Buy
22,701
+260
+1% +$29.3K 0.62% 31
2021
Q1
$2.43M Hold
22,441
0.61% 30
2020
Q4
$2.4M Hold
22,441
0.69% 31
2020
Q3
$1.97M Sell
22,441
-120
-0.5% -$11.3K 0.62% 35
2020
Q2
$2.21M Hold
22,561
0.76% 29
2020
Q1
$1.72M Sell
22,561
-1,044
-4% -$88.9K 0.68% 32
2019
Q4
$2.09M Hold
23,605
0.69% 30
2019
Q3
$1.76M Hold
23,605
0.63% 30
2019
Q2
$1.72M Buy
23,605
+527
+2% +$41.4K 0.61% 30
2019
Q1
$1.86M Sell
23,078
-105
-0.5% -$8.59K 0.68% 30
2018
Q4
$2.14M Sell
23,183
-2,244
-9% -$197K 0.92% 26
2018
Q3
$2.4M Buy
25,427
+400
+2% +$37.9K 0.98% 26
2018
Q2
$2.32M Sell
25,027
-475
-2% -$46.4K 1.06% 24
2018
Q1
$2.33M Sell
25,502
-8,258
-24% -$907K 1.07% 26
2017
Q4
$3.27M Sell
33,760
-498
-1% -$46.9K 1.45% 23
2017
Q3
$3.04M Sell
34,258
-179
-0.5% -$13.6K 1.45% 23
2017
Q2
$2.5M Hold
34,437
1.25% 24
2017
Q1
$2.24M Buy
34,437
+120
+0.3% +$7.54K 1.15% 24
2016
Q4
$2.15M Hold
34,317
1.16% 24
2016
Q3
$2.16M Hold
34,317
1.21% 24
2016
Q2
$2.13M Sell
34,317
-210
-0.6% -$12.8K 1.2% 26
2016
Q1
$1.97M Hold
34,527
1.15% 26
2015
Q4
$2.04M Sell
34,527
-6,987
-17% -$402K 1.23% 26
2015
Q3
$2.26M Buy
41,514
+279
+0.7% +$18.2K 1.46% 22
2015
Q2
$2.77M Hold
41,235
1.66% 21
2015
Q1
$2.41M Buy
41,235
+1,785
+5% +$108K 1.44% 21
2014
Q4
$2.58M Buy
39,450
+802
+2% +$50.6K 1.58% 22
2014
Q3
$2.23M Buy
38,648
+1,120
+3% +$62.2K 1.43% 22
2014
Q2
$2.12M Buy
37,528
+450
+1% +$23.6K 1.4% 22
2014
Q1
$1.91M Buy
37,078
+1,618
+5% +$81.8K 1.53% 22
2013
Q4
$1.87M Buy
+35,460
New +$1.74M 1.58% 22

Other funds holding ABBV

Founders Capital Management (Connecticut)'s ABBV Position: Q2 2026 in Review

Founders Capital Management (Connecticut) reduced its AbbVie (ABBV) stake by 0.31% in Q2 2026, selling an estimated $15.1K and leaving 22,823 shares worth $5.74M. The position accounts for 0.86% of the portfolio, ranked #24.

Founders Capital Management (Connecticut) first reported a position in ABBV in Q4 2013 and has held it in 51 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Founders Capital Management (Connecticut) held 22,823 shares of AbbVie worth $5.74M as of Q2 2026.
  • Founders Capital Management (Connecticut) sold 70 AbbVie shares in Q2 2026, an estimated $15.1K.
  • AbbVie made up 0.86% of Founders Capital Management (Connecticut)'s portfolio in Q2 2026, its #24 holding.
  • Founders Capital Management (Connecticut) first reported a position in AbbVie in Q4 2013 and has held it in 51 quarters since.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Founders Capital Management (Connecticut)'s 13F filing for Q2 2026, filed 20 Jul 2026.